NASHVILLE, Tenn. / May 14, 2025 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA)
Format: Fireside Chat, followed by 1x1 Investor Meetings
Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025
Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)
Format: 1x1 and Small Group Investor Meetings
Date/Time: Wednesday, May 28, 2025
Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting. Neither event will be webcast.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$39.64 |
| Daily Change: | 0.20 0.51 |
| Daily Volume: | 18,224 |
| Market Cap: | US$1.470B |
October 06, 2025 September 26, 2025 September 08, 2025 August 11, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
